Table 1.
Studies reporting survival data and prognostic factors for GSM patients.
| Study | Year of publication | No. of patients | Survival data | Prognostic factors |
|---|---|---|---|---|
| Kozak et al.2 | 2009 | 353 |
9 months (median OS) |
Younger age, RT, Extent of resection |
| Singh et al.11 | 2012 | 22 | 18.5 months (median OS) | TMZ |
| Walker et al.10 | 2013 | 46 | 12.5 months(median OS) | TMZ |
| Rath et al.24 | 2015 | 27 | 16.7 months (median OS) | TMZ |
| Castelli et al.17 | 2016 | 75 | 13 months (median OS) | RT, Treatment at recurrence |
| Adeberg et al.9 | 2016 | 37 | 13.4 months (median OS) | Trimodality therapy |
| Ma et al.8 | 2017 | 33 | 6.6 months (median OS) |
Age <50 years, Trimodality therapy |
| Frandsen et al.18 | 2018 | 1102 | 10.7 months (median OS) |
Age <65 years, Female sex, Fewer comorbidities, Trimodality therapy, GTR |
| Our series | 498 | 12.0 months (median DSS) |
Age at presentation, Tumour size, Metastasis state, Chemotherapy |